Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4),
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...
Zacks.com on MSN1d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback